5 Hrs
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
5 Hrsالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
5 HrsReady to play
Ready to play
A research team has developed a new method for designing cancer drugs to be more selective for the proteins that cause cancer, while reducing unwanted interactions that lead to side effects. The researchers used an improved version of covalent drugs, such as the drug "Dacomitinib," which precisely targets the amino acid cysteine. This approach reduces interactions with healthy proteins and enhances the safety of the treatment. Experiments on animals with lung tumors were successful, as the drug decreased tumor growth without noticeable side effects and improved absorption by the body. This approach allows for easy modification of existing drugs and represents a promising step toward developing safer and more effective cancer treatments.
Notice: This Is an AI-Generated Summary
Comments (0)